Literature DB >> 19834043

A high-throughput biophotonics instrument to screen for novel ocular photosensitizing therapeutic agents.

Mark C Butler1, Patrick N Itotia, Jack M Sullivan.   

Abstract

PURPOSE: High-throughput techniques are needed to identify and optimize novel photodynamic therapy (PDT) agents with greater efficacy and to lower toxicity. Novel agents with the capacity to completely ablate pathologic angiogenesis could be of substantial utility in diseases such as wet age-related macular degeneration (AMD).
METHODS: An instrument and approach was developed based on light-emitting diode (LED) technology for high-throughput screening (HTS) of libraries of potential chemical and biological photosensitizing agents. Ninety-six-well LED arrays were generated at multiple wavelengths and under rigorous intensity control. Cell toxicity was measured in 96-well culture arrays with the nuclear dye SYTOX Green (Invitrogen-Molecular Probes, Eugene, OR).
RESULTS: Rapid screening of photoactivatable chemicals or biological molecules has been realized in 96-well arrays of cultured human cells. This instrument can be used to identify new PDT agents that exert cell toxicity on presentation of light of the appropriate energy. The system is further demonstrated through determination of the dose dependence of model compounds having or lacking cellular phototoxicity. Killer Red (KR), a genetically encoded red fluorescent protein expressed from transfected plasmids, is examined as a potential cellular photosensitizing agent and offers unique opportunities as a cell-type-specific phototoxic protein.
CONCLUSIONS: This instrument has the capacity to screen large chemical or biological libraries for rapid identification and optimization of potential novel phototoxic lead candidates. KR and its derivatives have unique potential in ocular gene therapy for pathologic angiogenesis or tumors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19834043      PMCID: PMC2868480          DOI: 10.1167/iovs.08-2862

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  40 in total

1.  A screen for photoirritants in cultured cells.

Authors:  M B Dixit; M West; L K Earl; W W Lovell
Journal:  Toxicol In Vitro       Date:  1994-08       Impact factor: 3.500

2.  Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1999-10

3.  Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study.

Authors:  J W Miller; U Schmidt-Erfurth; M Sickenberg; C J Pournaras; H Laqua; I Barbazetto; L Zografos; B Piguet; G Donati; A M Lane; R Birngruber; H van den Berg; A Strong; U Manjuris; T Gray; M Fsadni; N M Bressler; E S Gragoudas
Journal:  Arch Ophthalmol       Date:  1999-09

4.  High throughput screening (HTS) for phototoxicity hazard using the in vitro 3T3 neutral red uptake assay.

Authors:  P A Jones; A V King
Journal:  Toxicol In Vitro       Date:  2003 Oct-Dec       Impact factor: 3.500

5.  Effective accumulation of polyion complex micelle to experimental choroidal neovascularization in rats.

Authors:  Ryuichi Ideta; Yasuo Yanagi; Yasuhiro Tamaki; Fumitaka Tasaka; Atsushi Harada; Kazunori Kataoka
Journal:  FEBS Lett       Date:  2004-01-16       Impact factor: 4.124

6.  Liposomal benzoporphyrin derivative verteporfin photodynamic therapy. Selective treatment of choroidal neovascularization in monkeys.

Authors:  M Kramer; J W Miller; N Michaud; R S Moulton; T Hasan; T J Flotte; E S Gragoudas
Journal:  Ophthalmology       Date:  1996-03       Impact factor: 12.079

7.  Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases.

Authors:  M Friedlander; C L Theesfeld; M Sugita; M Fruttiger; M A Thomas; S Chang; D A Cheresh
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

8.  Murine endothelial cell lines as models of tumor endothelial cells.

Authors:  Jennifer Walter-Yohrling; Sharon Morgenbesser; Cecile Rouleau; Rebecca Bagley; Michelle Callahan; William Weber; Beverly A Teicher
Journal:  Clin Cancer Res       Date:  2004-03-15       Impact factor: 12.531

9.  Automated, quantitative screening assay for antiangiogenic compounds using transgenic zebrafish.

Authors:  T Cameron Tran; Blossom Sneed; Jamil Haider; Delali Blavo; Audrey White; Temitope Aiyejorun; Timothy C Baranowski; Amy L Rubinstein; Thanh N Doan; Raymond Dingledine; Eric M Sandberg
Journal:  Cancer Res       Date:  2007-12-01       Impact factor: 12.701

10.  Reactive oxygen species (ROS)-induced ROS release: a new phenomenon accompanying induction of the mitochondrial permeability transition in cardiac myocytes.

Authors:  D B Zorov; C R Filburn; L O Klotz; J L Zweier; S J Sollott
Journal:  J Exp Med       Date:  2000-10-02       Impact factor: 14.307

View more
  5 in total

1.  A high-throughput photodynamic therapy screening platform with on-chip control of multiple microenvironmental factors.

Authors:  Xia Lou; Gwangseong Kim; Hyung Ki Yoon; Yong-Eun Koo Lee; Raoul Kopelman; Euisik Yoon
Journal:  Lab Chip       Date:  2014-03-07       Impact factor: 6.799

2.  Hypericin-photodynamic therapy leads to interleukin-6 secretion by HepG2 cells and their apoptosis via recruitment of BH3 interacting-domain death agonist and caspases.

Authors:  M Barathan; V Mariappan; E M Shankar; B J J Abdullah; K L Goh; J Vadivelu
Journal:  Cell Death Dis       Date:  2013-06-27       Impact factor: 8.469

Review 3.  Medication Trends for Age-Related Macular Degeneration.

Authors:  Yeon-Kyoung Cho; Dae-Hun Park; In-Chul Jeon
Journal:  Int J Mol Sci       Date:  2021-10-31       Impact factor: 5.923

4.  Hypericin-photodynamic therapy induces human umbilical vein endothelial cell apoptosis.

Authors:  Qian Zhang; Zhuo-heng Li; Yuan-yuan Li; San-jun Shi; Shi-wen Zhou; Yuan-yuan Fu; Qing Zhang; Xue Yang; Ruo-qiu Fu; Lai-chun Lu
Journal:  Sci Rep       Date:  2015-12-17       Impact factor: 4.379

5.  Hypericin-photodynamic therapy inhibits proliferation and induces apoptosis in human rheumatoid arthritis fibroblast-like synoviocytes cell line MH7A.

Authors:  Kun Zhang; Shan Gao; JiaYi Guo; GuoHua Ni; Zhe Chen; Feng Li; XiaoLei Zhu; YongBing Wen; YanXing Guo
Journal:  Iran J Basic Med Sci       Date:  2018-02       Impact factor: 2.699

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.